Erythropoietin administration to improve graft survival
US7459152B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 23, 2004 |
| Grant date | Dec 2, 2008 |
| Priority date | — |
| Expiry date | Jul 28, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods, compounds and kits for increasing the viability of cells. The methods involve treating cells that make up a tissue graft with erythropoietin before, during or after delivery or administration. The method can employ cells of different types, including cells of neural or paraneural origin, such as adrenal chromaffin cells. Also useful are cell lines grown in vitro. Cells not of neural or paraneural origin, such as fibroblasts, may also be used following genetic alteration to express a desired neural product such as a neurotransmitter or a neuronal growth factor. The method is used to treat neurological diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, and traumatic brain or spinal cord injury.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.